rxstat › Shortages › Quizartinib

Quizartinib (Vanflyta) shortage status

Widespread shortage

Source: Health Canada shortage reports · Updated Oct 16, 2026

Quizartinib is in a widespread shortage in Canada. 2 of 2 reported products are affected. The latest manufacturer estimate for full recovery is Oct 23, 2026.
Products affected
2 / 2
In shortage since
Sep 28, 2026
Est. full return
Oct 23, 2026
Reports on file
2
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Book a pharmacist appointment
Need your prescription switched?
When every manufacturer is affected, an online doctor can assess your situation and prescribe an alternative.
See a doctor online

Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.

Reports by product

The DIN is printed on your prescription label.

Active shortage
VANFLYTA
17.7MG · TABLET · DAIICHI SANKYO PHARMA CANADA LIMITED
DIN 02558351 · since Sep 28, 2026, est. end Oct 23, 2026 · Interruption of Supply. Foreign authorized product is available.
Active shortage
VANFLYTA
26.5MG · TABLET · DAIICHI SANKYO PHARMA CANADA LIMITED
DIN 02558378 · since Oct 14, 2026, est. end Oct 23, 2026 · Interruption of supply. Foreign authorized product is available.

What's happening

Quizartinib is currently affected by 2 active shortage reports filed with Health Canada by DAIICHI SANKYO PHARMA CANADA LIMITED.

The reported causes are: interruption of supply. foreign authorized product is available; interruption of supply. foreign authorized product is available. Manufacturers must report shortages, but end-date estimates are their own projections and often move.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Recent changes

Common questions

When will Quizartinib be back in stock in Canada?

The latest manufacturer estimate is Oct 23, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.

Why is Quizartinib in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Possible alternatives in the same class

Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.

Capmatinib (Tabrecta) No current shortage Larotrectinib (Vitrakvi) No current shortage Bosutinib Partial shortage 1 of 1 reported products affected Dasatinib (Sprycel) Partial shortage 1 of 14 reported products affected · est. return Sep 21, 2027 Everolimus (Afinitor) Partial shortage 1 of 14 reported products affected · est. return Aug 10, 2027 Gefitinib Partial shortage 1 of 4 reported products affected · est. return Dec 31, 2026

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.